Tuesday, June 12, 2007 1:02:29 PM
I saw on iHub that the advantage for the triple-therapy arm was over 10% :
http://www.investorshub.com/boards/read_msg.asp?message_id=20377556
But it actually did NOT make the cut, if you read the news release:
Of patients that completed 12 weeks of therapy, 72.2 percent .......triple combination therapy (arm B) achieved HCV PCR-negativity, compared to 61.5 percent ......There were three discontinuations from the study, all due to adverse events (AEs)...... valopicitabine-related gastrointestinal toxicity. The two other AEs, including a serious adverse event (SAE).....occurred in the triple combination arm (arm B).
That checks out @ 3 patients left out who did not make the grade; instead of 72.2% of 36 on triple (exactly 26 of course), it's 26/39 which is 66.66 %. Compare that with 24/39 on SoC. Is there an investment thesis here ?
So the margin is 5.5% not 10%. Almost certainly NOT statistically significant. Actually using Fischer's Exact Test the result is:
"The two-tailed P value equals 0.8137"
Plus all the discontinuations were due to AEs on this "efficaceous" arm.
Sooner or later people (analysts etc) will see through this release. I expect IDIX to drift lower now, it's too vulnerable.
"....on the biotech battle-field, you need some élan...."
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering • SNWV • Oct 18, 2024 9:31 AM
Vocodia Addresses Recent Stock Price Movement and Future Strategic Partnerships • VHAI • Oct 18, 2024 9:00 AM
Mass Megawatts Announces the Start of an Online Discount Solar Energy Equipment Business with Revenue Recognized for the First Time Since Year 2010 in this Fiscal Quarter • MMMW • Oct 18, 2024 7:32 AM
Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM